Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal D ...
October 6, 2026
–ADOA is the most common inherited optic nerve disorder and is primarily caused by variants in the OPA1 gene that result in ...Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevun ...
October 5, 2026
– Analysis of the Phase 3 EMPEROR key secondary endpoint of changes in cognition and behavior will be performed using a multi ...Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advan ...
September 23, 2026
–Mr. Cumbo brings deep experience commercializing new medicines for people with rare genetic diseases– –Company announces ret ...Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
September 16, 2026
BEDFORD, Mass. --(BUSINESS WIRE)--Sep. 16, 2026-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicate ...Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorev ...
September 3, 2026
–4-year data from the Phase 1/2a open-label extension (OLE) studies showed substantial and durable reductions in seizures and ...Stoke Therapeutics to Present at the Cantor Global Healthcare Conference
September 2, 2026
BEDFORD, Mass. --(BUSINESS WIRE)--Sep. 2, 2026-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated ...Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigatio ...
September 1, 2026
–4-year data from the Phase 1/2a open-label extension (OLE) studies support the potential disease-modifying effects of zorevu ...Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
August 18, 2026
BEDFORD, Mass. --(BUSINESS WIRE)--Aug. 18, 2026-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicate ...Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
August 5, 2026
BEDFORD, Mass. --(BUSINESS WIRE)--Aug. 5, 2026-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated ...Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates
August 3, 2026
– Phase 3 EMPEROR study of zorevunersen in Dravet syndrome: Enrollment of 162 patients complete with data readout anticipat ...Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Update ...
July 27, 2026
BEDFORD, Mass. --(BUSINESS WIRE)--Jul. 27, 2026-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicate ...Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
July 16, 2026
BEDFORD, Mass. --(BUSINESS WIRE)--Jul. 16, 2026-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicate ...Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer
July 13, 2026
–Dr. McCauley brings more than 25 years of experience building high-performing R&D organizations and translating early scient ...Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunerse ...
June 30, 2026
—Company plans to initiate a rolling U.S. NDA submission to the FDA in the first quarter of 2027— —Phase 3 data readout antic ...Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
June 16, 2026
BEDFORD, Mass. --(BUSINESS WIRE)--Jun. 16, 2026-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicate ...Stoke Therapeutics to Present at Upcoming Investor Conferences in June
May 28, 2026
BEDFORD, Mass. --(BUSINESS WIRE)--May 28, 2026-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated ...Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
May 18, 2026
BEDFORD, Mass. --(BUSINESS WIRE)--May 18, 2026-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated ...Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates
May 7, 2026
– New 4-year longitudinal data from the Phase 1/2a open-label extension (OLE) studies provide additional support for the dise ...Stoke Therapeutics to Host Webcast and Conference Call to Discuss First Quarter 2026 Business and Financial Updates
April 30, 2026
BEDFORD, Mass. --(BUSINESS WIRE)--Apr. 30, 2026-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicate ...Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
April 16, 2026
BEDFORD, Mass. --(BUSINESS WIRE)--Apr. 16, 2026-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicate ...Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
April 8, 2026
BEDFORD, Mass. --(BUSINESS WIRE)--Apr. 8, 2026-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated ...Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors
April 7, 2026
BEDFORD, Mass. --(BUSINESS WIRE)--Apr. 7, 2026-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated ...Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
March 17, 2026
BEDFORD, Mass. --(BUSINESS WIRE)--Mar. 17, 2026-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicate ...The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in D ...
March 4, 2026
–Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with t ...Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
February 24, 2026
BEDFORD, Mass. --(BUSINESS WIRE)--Feb. 24, 2026-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicate ...